Page 1 of 1

Ocrelizumab shows effectiveness in Multiple Sclerosis

Posted: Thu Oct 20, 2011 12:21 am
by MSUK
Image

Roche Holding AG said Thursday that a phase II showed its experimental drug ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years. Roche said phase III trials underway to investigate ocrelizumab in two forms of MS

96-week results from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease. The study showed that the significant reduction in disease activity as measured by the total number of active brain lesions and relapses previously reported for 24 weeks, was maintained through 96 weeks.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397